Related Experiment Videos

Polymethacrylic acid: induction of lymphocytosis and tissue distribution

Cell and Tissue Kinetics
|September 1, 1975
PubMed

Insights

Polymethacrylic acid (PMAA) significantly increases lymphocyte counts in peripheral blood across multiple species via intravenous administration. This immune response is localized primarily to the spleen and lymph nodes, suggesting a key role in lymphocytosis.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Polymethacrylic acid (PMAA) is known to affect immune cell populations.
  • Understanding the specific effects and mechanisms of PMAA on lymphocytes is crucial for potential therapeutic applications.

Purpose of the Study:

  • To investigate the lymphocytosis-inducing effects of polymethacrylic acid (PMAA) in various animal models.
  • To determine the optimal administration route, dosage, and timing for PMAA-induced lymphocytosis.
  • To identify the primary sites of PMAA accumulation and its role in the immune response.

Main Methods:

  • Intravenous administration of PMAA to rats, goats, and calves.
  • Dose-response and time-course studies to assess lymphocytosis.
  • Administration of radiolabeled PMAA (125I and 14C) to rats to track tissue distribution.
  • Whole-body perfusion to differentiate blood-borne from tissue-bound radioactivity.

Main Results:

  • Intravenous PMAA administration induced a three-fold increase in lymphocytes in rats, goats, and calves.
  • Maximum lymphocytosis occurred at 3 hours post-administration with doses exceeding 30 mg/kg.
  • Significant accumulation of radiolabeled PMAA was observed in the spleen, lungs, liver, kidney, adrenals, and mesenteric lymph nodes, with higher specificity for spleen and lymph nodes.

Conclusions:

  • PMAA effectively induces lymphocytosis, particularly when administered intravenously.
  • The spleen and lymph nodes are key sites for PMAA action in lymphocytosis.
  • PMAA's distribution suggests potential for stem cell mobilization and clinical applications, such as in ECIB therapy.

Related Concept Videos